POLYX / TRY

POLYX / USDT

THETA / USDC

THETA / TRY

THETA / USDT

THETA / BTC

ONG / USDT

ONG / BTC

NOM / TRY

NOM / USDT

D / USDT

D / TRY

HEMI / TRY

HEMI / USDT

HEMI / USDC

ONT / BTC

ONT / USDT

ONT / TRY

NIGHT / BNB

币安人生 / USDC

THE BYKE HOSPITALITY LTD

PRANIK LOGISTICS LIMITED

GSS INFOTECH LIMITED

BOMBAY SUPER HYBRID SEEDS

BROOKS LAB LIMITED

CONFIDENCE PETRO IND LTD.

LATENT VIEW ANALYTICS LTD

ORIENTAL TRIMEX LTD

ATC ENERGIES SYSTEM LTD

HLV LIMITED

R&B DENIMS LIMITED

AVG LOGISTICS LIMITED

MAHA RASHTRA APEX COPR. L

CURIS LIFESCIENCES LTD

HILTON METAL FORGING LTD

ACUTAAS CHEMICALS LIMITED

SUPREME HOLDIN N HOSP I L

SHIVASHRIT FOODS LIMITED

SILKY OVERSEAS LIMITED

KAUSHALYA LOGISTICS LTD

Click here to get full coverage on Biocon trims workforce as Biologics merger nears completion - Moneycontrol.com

Biocon trims workforce as Biologics merger nears completion  Moneycontrol.com

Biocon trims workforce as Biologics merger nears completion - Moneycontrol.com

Click here to get full coverage on Biocon Foundation Launches BioWISE to Train 25 Women in STEM - deccanherald.com

Biocon Foundation Launches BioWISE to Train 25 Women in STEM  deccanherald.com

Biocon Foundation Launches BioWISE to Train 25 Women in STEM - deccanherald.com

Click here to get full coverage on Biocon aims for revenue surge with rollout of generic weight-loss drugs - Reuters

Biocon aims for revenue surge with rollout of generic weight-loss drugs  Reuters

Biocon aims for revenue surge with rollout of generic weight-loss drugs - Reuters

Click here to get full coverage on Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026 - PR Newswire

Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026  PR Newswire

Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026 - PR Newswire

Click here to get full coverage on Maninder Kapoor Puri leaves Biocon to take up CHRO role at Syngene - People Matters - HR News

Maninder Kapoor Puri leaves Biocon to take up CHRO role at Syngene  People Matters - HR News

Maninder Kapoor Puri leaves Biocon to take up CHRO role at Syngene - People Matters - HR News

Click here to get full coverage on Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Biocon buys out Viatris and others from biosimilar subsidiary  Fierce Pharma

Biocon buys out Viatris and others from biosimilar subsidiary - Fierce Pharma

Click here to get full coverage on Biocon Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals - Markets Mojo

Biocon Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals  Markets Mojo

Biocon Ltd. Technical Momentum Shifts Amid Mixed Indicator Signals - Markets Mojo

Click here to get full coverage on Maninder Kapoor Puri exits Biocon, joins Syngene as CHRO - HR Katha

Maninder Kapoor Puri exits Biocon, joins Syngene as CHRO  HR Katha

Maninder Kapoor Puri exits Biocon, joins Syngene as CHRO - HR Katha

Click here to get full coverage on Viatris signs agreements with Biocon on $815m stake sale - Pharmaceutical Technology

Viatris signs agreements with Biocon on $815m stake sale  Pharmaceutical Technology

Viatris signs agreements with Biocon on $815m stake sale - Pharmaceutical Technology

Click here to get full coverage on Biocon Limited to integrate Biocon Biologics - The Pharma Letter

Biocon Limited to integrate Biocon Biologics  The Pharma Letter

Biocon Limited to integrate Biocon Biologics - The Pharma Letter

Click here to get full coverage on Sun Pharma, Aurobindo, Biocon fall as US mulls 100% tariffs on drug imports - MSN

Sun Pharma, Aurobindo, Biocon fall as US mulls 100% tariffs on drug imports  MSN

Sun Pharma, Aurobindo, Biocon fall as US mulls 100% tariffs on drug imports - MSN

Click here to get full coverage on Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Biocon opens first US manufacturing facility in New Jersey  NJBIZ

Biocon opens first US manufacturing facility in New Jersey - NJBIZ

Click here to get full coverage on Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion - Forbes

Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion  Forbes

Indian Tycoon Kiran Mazumdar-Shaw’s Biocon Buyout Deal Values Biologics Unit At $5.5 Billion - Forbes

Click here to get full coverage on Too many women STEM students drop out before entering careers: Kiran Mazumdar-Shaw - The Hindu

Too many women STEM students drop out before entering careers: Kiran Mazumdar-Shaw  The Hindu

Too many women STEM students drop out before entering careers: Kiran Mazumdar-Shaw - The Hindu

Click here to get full coverage on Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited  PR Newswire

Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited - PR Newswire

Click here to get full coverage on Biocon secures global rights to biosimilar adalimumab - The Pharma Letter

Biocon secures global rights to biosimilar adalimumab  The Pharma Letter

Biocon secures global rights to biosimilar adalimumab - The Pharma Letter

Click here to get full coverage on US proposal to halve biosimilar development costs for India's Biocon, top exec says - Reuters

US proposal to halve biosimilar development costs for India's Biocon, top exec says  Reuters

US proposal to halve biosimilar development costs for India's Biocon, top exec says - Reuters

Click here to get full coverage on Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - PR Newswire

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options  PR Newswire

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options - PR Newswire

Click here to get full coverage on Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: - economictimes.com

Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern:  economictimes.com

Trump's 100% tariff on patented drugs has limited impact on Indian pharma, rising protectionism a concern: - economictimes.com

Click here to get full coverage on Inside “Glenmore,” the Spanish style Bengaluru villa of Biocon founder Kiran Mazumdar-Shaw - The Times of India

Inside “Glenmore,” the Spanish style Bengaluru villa of Biocon founder Kiran Mazumdar-Shaw  The Times of India

Inside “Glenmore,” the Spanish style Bengaluru villa of Biocon founder Kiran Mazumdar-Shaw - The Times of India

Click here to get full coverage on Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey  PR Newswire

Biocon Inaugurates First U.S. Manufacturing Facility in Cranbury, New Jersey - PR Newswire

Click here to get full coverage on Biocon Biologics to Expand Biosimilar Oncology Portfolio, - GlobeNewswire

Biocon Biologics to Expand Biosimilar Oncology Portfolio,  GlobeNewswire

Biocon Biologics to Expand Biosimilar Oncology Portfolio, - GlobeNewswire

Click here to get full coverage on Biocon to Add Pembrolizumab, Nivolumab & Trastuzumab SC Biosimilars to its Portfolio - Pearce IP

Biocon to Add Pembrolizumab, Nivolumab & Trastuzumab SC Biosimilars to its Portfolio  Pearce IP

Biocon to Add Pembrolizumab, Nivolumab & Trastuzumab SC Biosimilars to its Portfolio - Pearce IP

Click here to get full coverage on Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw to Receive Honorary Degree from Keck Graduate Institute - Yahoo Finance

Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw to Receive Honorary Degree from Keck Graduate Institute  Yahoo Finance

Biocon Founder and Executive Chairperson Kiran Mazumdar-Shaw to Receive Honorary Degree from Keck Graduate Institute - Yahoo Finance

Click here to get full coverage on Biocon names Shreehas Tambe CEO, replacing Siddharth Mittal - People Matters - HR News

Biocon names Shreehas Tambe CEO, replacing Siddharth Mittal  People Matters - HR News

Biocon names Shreehas Tambe CEO, replacing Siddharth Mittal - People Matters - HR News

Click here to get full coverage on Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ  Investment Monitor

Biocon launches first US manufacturing facility in Cranbury, NJ - Investment Monitor

Click here to get full coverage on Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion - Bloomberg.com

Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion  Bloomberg.com

Biocon Moves to Fully Own Biologics Unit Valued at $5.5 Billion - Bloomberg.com

Click here to get full coverage on Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360

Biocon Challenges Regeneron Over UK Retinal Pharma Patent  Law360

Biocon Challenges Regeneron Over UK Retinal Pharma Patent - Law360

Click here to get full coverage on Biocon’s new CEO Tambe sharpens focus on core therapies, global mkts - The Times of India

Biocon’s new CEO Tambe sharpens focus on core therapies, global mkts  The Times of India

Biocon’s new CEO Tambe sharpens focus on core therapies, global mkts - The Times of India

Click here to get full coverage on Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026 - Pearce IP

Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026  Pearce IP

Biocon Secures UK/EU/ROW Settlement with Regeneron/Bayer for Biosimilar Aflibercept; UK Launch in Jan 2026 - Pearce IP

Click here to get full coverage on Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe - insights.citeline.com

Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe  insights.citeline.com

Biocon Strikes Aflibercept Deal And Launches Liraglutide In Europe - insights.citeline.com

Click here to get full coverage on Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites  Manufacturing Dive

Samsung Biologics, Amgen and Biocon invest in US pharma sites - Manufacturing Dive

Click here to get full coverage on Biocon Biologics unveils 3 new oncology biosimilars - Drug Store News

Biocon Biologics unveils 3 new oncology biosimilars  Drug Store News

Biocon Biologics unveils 3 new oncology biosimilars - Drug Store News

Click here to get full coverage on Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars  Yahoo Finance

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Click here to get full coverage on Genentech Says Biocon Importing Infringing Cancer Drugs - Law360

Genentech Says Biocon Importing Infringing Cancer Drugs  Law360

Genentech Says Biocon Importing Infringing Cancer Drugs - Law360

Click here to get full coverage on Biocon Inaugurates First US Manufacturing Facility in Cranbury - njbmagazine.com

Biocon Inaugurates First US Manufacturing Facility in Cranbury  njbmagazine.com

Biocon Inaugurates First US Manufacturing Facility in Cranbury - njbmagazine.com

Click here to get full coverage on India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year - Bloomberg.com

India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year  Bloomberg.com

India’s Biocon Aims to Lead Copycat Wegovy Sales in Canada From Next Year - Bloomberg.com

Click here to get full coverage on Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps down - economictimes.com

Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps down  economictimes.com

Biocon names insider Shreehas Tambe as MD & CEO for 5 years as Siddharth Mittal steps down - economictimes.com

Click here to get full coverage on The $100 Million Liraglutide Pivot: Why Biocon Is Prioritising US Exports Over The Indian Price War - NDTV Profit

The $100 Million Liraglutide Pivot: Why Biocon Is Prioritising US Exports Over The Indian Price War  NDTV Profit

The $100 Million Liraglutide Pivot: Why Biocon Is Prioritising US Exports Over The Indian Price War - NDTV Profit

Click here to get full coverage on Maninder Kapoor Puri Moves To Syngene As CHRO, Steps Down From Biocon - BW People

Maninder Kapoor Puri Moves To Syngene As CHRO, Steps Down From Biocon  BW People

Maninder Kapoor Puri Moves To Syngene As CHRO, Steps Down From Biocon - BW People

Click here to get full coverage on Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr; Q3FY26 EBITDA at Rs 951 Cr; Q3FY26 Net Profit at Rs 144 Cr - Biocon

Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr; Q3FY26 EBITDA at Rs 951 Cr; Q3FY26 Net Profit at Rs 144 Cr  Biocon

Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr; Q3FY26 EBITDA at Rs 951 Cr; Q3FY26 Net Profit at Rs 144 Cr - Biocon

Click here to get full coverage on Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S. - Miami Herald

Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S.  Miami Herald

Biocon Biologics And Civica Team To Launch Private-Label Insulin Glargine In The U.S. - Miami Herald

Click here to get full coverage on Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - LAmag

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients  LAmag

Biocon Biologics And Civica Bring Lower-Cost Insulin Glargine To U.S. Patients - LAmag

Click here to get full coverage on Aurobindo Pharma, Biocon, Glenmark Shares Plunge Over 5% as Nifty Pharma Drops 3.5% - meyka.com

Aurobindo Pharma, Biocon, Glenmark Shares Plunge Over 5% as Nifty Pharma Drops 3.5%  meyka.com

Aurobindo Pharma, Biocon, Glenmark Shares Plunge Over 5% as Nifty Pharma Drops 3.5% - meyka.com

Click here to get full coverage on SBI, ICICI Funds Said to Lead Bids in Oversubscribed Biocon Sale - Bloomberg.com

SBI, ICICI Funds Said to Lead Bids in Oversubscribed Biocon Sale  Bloomberg.com

SBI, ICICI Funds Said to Lead Bids in Oversubscribed Biocon Sale - Bloomberg.com

Click here to get full coverage on Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States  GlobeNewswire

Biocon Biologics Expands Diabetes Portfolio with FDA Approval of Kirsty™, the First and Only Interchangeable Rapid-Acting Insulin Aspart in the United States - GlobeNewswire

Click here to get full coverage on Biocon Ltd. is Rated Hold by MarketsMOJO - Markets Mojo

Biocon Ltd. is Rated Hold by MarketsMOJO  Markets Mojo

Biocon Ltd. is Rated Hold by MarketsMOJO - Markets Mojo

Click here to get full coverage on Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars  Yahoo Finance

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars - Yahoo Finance

Click here to get full coverage on Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea  Ophthalmology Times

Health Canada approves Biocon's Yesafili, biosimilar to Eylea - Ophthalmology Times

Click here to get full coverage on Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says  Reuters

Biocon eyes generic Wegovy obesity drug launch in India, Canada in next 2 years, CEO says - Reuters

Click here to get full coverage on Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29% - Biocon

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%  Biocon

Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29% - Biocon

Click here to get full coverage on Biocon Secures EU/ROW Deal for Biosimilar Denosumab Following Amgen Settlement, Launch in EU in December 2025 - Pearce IP

Biocon Secures EU/ROW Deal for Biosimilar Denosumab Following Amgen Settlement, Launch in EU in December 2025  Pearce IP

Biocon Secures EU/ROW Deal for Biosimilar Denosumab Following Amgen Settlement, Launch in EU in December 2025 - Pearce IP

Click here to get full coverage on Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B - Pearce IP

Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B  Pearce IP

Biocon Limited to Wholly Acquire Biocon Biologics, Valued at USD 5.5B - Pearce IP

Click here to get full coverage on Biocon to merge biologics unit in $5.5 billion deal - The Times of India

Biocon to merge biologics unit in $5.5 billion deal  The Times of India

BIOCON

Price Chart

Key Statistics

Technicals

About BIOCON

Latest News

Biocon trims workforce as Biologics merger nears completion - Moneycontrol.com

Biocon Foundation Launches BioWISE to Train 25 Women in STEM - deccanherald.com

Biocon aims for revenue surge with rollout of generic weight-loss drugs - Reuters

Advanced Charts

Top Gainers

Top Losers